Unidad Especializada en Tabaquismo, c/ Santacruz del Marcenado, 9 piso 2, Madrid 28015, Spain.
Nicotine Tob Res. 2012 Sep;14(9):1035-9. doi: 10.1093/ntr/nts001. Epub 2012 Feb 17.
Smoking is the main cause of chronic obstructive pulmonary disease (COPD), and smoking cessation is the only treatment shown to be effective in arresting the progression of COPD. Different epidemiological and population-based studies have shown smokers with COPD to have specific smoking characteristics that differentiate them from the rest of smokers and which complicate smoking cessation. The main objective of this study is to analyze the effectiveness and safety of drug treatments for smoking cessation in smokers with severe or very severe COPD.
Smokers with severe or very severe COPD (Global Initiative for Chronic Obstructive Lung Disease stages III and IV) received treatment for smoking cessation. The treatment program consisted of a combination of behavioral therapy and drug treatment. Patients were followed up at 1, 2, 4, 6, 8, 10, 12, 18, and 24 weeks after the quit date.
Four hundred seventy-two patients were seen, 65% were male, and their mean age was 58.3 (9.8). They smoked an average of 29.7 (13.4) cigarettes/day, and their mean Fagerström test for nicotine dependence score was 7.4 (2.1). Continuous abstinence rate from 9 to 24 weeks (CAR 9-24) was 48.5%. According to type of treatment used, CAR 9-24 for nicotine replacement therapy (NRT), bupropion, and varenicline were 38.2%, 55.6%, and 58.3%, respectively. Varenicline was more effective than nicotine patches: 61% versus 44.1% (odds ratio: 1.98; 95% CI: 1.25-3.12; p = .003). NRT was the treatment producing the fewest adverse effects. The onset of psychiatric symptoms due to medication was rare and evenly distributed across groups.
This study shows that smokers with severe or very severe COPD are predominantly males with a high degree of physical dependence upon nicotine. CAR 9-24 was 48.5%. Varenicline and bupropion yielded higher abstinence rates than NRT. Varenicline was more effective than nicotine patches: all types of treatments were safe.
吸烟是慢性阻塞性肺疾病(COPD)的主要病因,而戒烟是唯一被证明可有效阻止 COPD 进展的治疗方法。不同的流行病学和基于人群的研究表明,患有 COPD 的吸烟者具有特定的吸烟特征,这些特征使他们与其他吸烟者区分开来,并使戒烟复杂化。本研究的主要目的是分析药物戒烟治疗对重度或极重度 COPD 吸烟者的有效性和安全性。
患有重度或极重度 COPD(慢性阻塞性肺疾病全球倡议分期 III 和 IV)的吸烟者接受戒烟治疗。治疗方案包括行为疗法和药物治疗相结合。患者在戒烟日期后 1、2、4、6、8、10、12、18 和 24 周进行随访。
共观察了 472 名患者,其中 65%为男性,平均年龄为 58.3(9.8)岁。他们平均每天吸烟 29.7(13.4)支,平均尼古丁依赖 Fagerström 测试评分为 7.4(2.1)分。9 至 24 周的连续戒烟率(CAR9-24)为 48.5%。根据使用的治疗类型,尼古丁替代疗法(NRT)、安非他酮和伐尼克兰的 CAR9-24 分别为 38.2%、55.6%和 58.3%。伐尼克兰比尼古丁贴片更有效:61%比 44.1%(比值比:1.98;95%CI:1.25-3.12;p =.003)。NRT 的副作用最少。由于药物引起的精神症状很少见,且在各组之间分布均匀。
本研究表明,患有重度或极重度 COPD 的吸烟者主要为男性,对尼古丁有高度的生理依赖。CAR9-24 为 48.5%。伐尼克兰和安非他酮的戒烟率高于 NRT。伐尼克兰比尼古丁贴片更有效:所有类型的治疗都是安全的。